|
Session 118-Poster Abstracts
Pharmacokinetics and Pharmacodynamics of Entry Inhibitors
Wednesday, 2-4 pm; Poster Hall |
| 597 |
Achieving a Target Exposure to PRO 140 Results in Maximal Viral Load Reduction by Subcutaneous or Intravenous Administration
Melanie Thompson*1, J Jacobson2, M Hole3, P D’Ambrosio3, and S Morris3
1AIDS Res Consortium of Atlanta, GA, US; 2Drexel Univ, Philadelphia, PA, US; and 3Progenics Pharmaceuticals, Inc, Tarrytown, NY, US |
598
 |
Pharmacokinetics and Pharmacodynamics of TBR 652, a Chemokine Receptor 5 Antagonist, in HIV-1-infected, ART-experienced, CCR5 Antagonist–Naïve Patients
David Martin*1, S Palleja1, L Pheng2, M M Trinh2, J-F Marier2, and J Sapirstein1
1Tobira Therapeutics, Inc, Princeton, NJ, US and 2Pharsight Corp, Montreal, Canada |
599
|
Solute Carrier Organic Anion Transporter 1B1 Mediates Transport of Maraviroc Using a X. leavis Model
Marco Siccardi*1,2, D Moss1, W-S Kwan1, A D’Avolio2, S Bonora2, S Khoo1, D Back1, G Di Perri2, and A Owen1
1Univ of Liverpool, UK and 2Univ of Turin, Italy |
|
